The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Open accessAbstract
Autistic Spectrum Disorder (ASD) is a complex neurodevelopmental brain disorder characterized by two core behavioral symptoms, namely impairments in social communication and restricted/repetitive behavior. The molecular mechanisms underlying ASD are not well understood. Recent genetic as well as non-genetic animal models contributed significantly in understanding the pathophysiology of ASD, as they establish autism-like behavior in mice and rats. Among the genetic causes, several chromosomal mutations including duplications or deletions could be possible causative factors of ASD. In addition, the biochemical basis suggests that several brain neurotransmitters, e.g., dopamine (DA), serotonin (5-HT), gamma-amino butyric acid (GABA), acetylcholine (ACh), glutamate (Glu) and histamine (HA) participate in the onset and progression of ASD. Despite of convincible understanding, risperidone and aripiprazole are the only two drugs available clinically for improving behavioral symptoms of ASD following approval by Food and Drug Administration (FDA). Till date, up to our knowledge there is no other drug approved for clinical usage specifically for ASD symptoms. However, many novel drug candidates and classes of compounds are underway for ASD at different phases of preclinical and clinical drug development. In this review, the diversity of numerous aetiological factors and the alterations in variety of neurotransmitter generation, release and function linked to ASD are discussed with focus on drugs currently used to manage neuropsychiatric symptoms related to ASD. The review also highlights the clinical development of drugs with emphasis on their pharmacological targets aiming at improving core symptoms in ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–245 of 245
Once-monthly paliperidone injection for the treatment of schizophrenia
Bishara, D. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s8505 · Cited by 58
Galantamine may be effective in treating autistic disorder
Niederhofer, H., Staffen, W., & Mair, A. (2002) · BMJ · doi:10.1136/bmj.325.7377.1422/a · Cited by 55
Baronio, D., Gonchoroski, T., Castro, K., Zanatta, G., Gottfried, C., & Riesgo, R. (2014) · Annals of General Psychiatry · doi:10.1186/s12991-014-0034-y · Cited by 55
Carminati, G. G., Deriaz, N., & Bertschy, G. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.002 · Cited by 54
Brief report: A synopsis of an open-trial of naltrexone treatment of autism with four children
Panksepp, J., & Lensing, P. (1991) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02284764 · Cited by 54
Boellner, S., Pennick, M., Fiske, K., Lyne, A., & Shojaei, A. H. (2007) · Pharmacotherapy · doi:10.1592/phco.27.9.1253 · Cited by 54
The emerging roles of MicroRNAs in autism spectrum disorders
Fregeac, J., Colleaux, L., & Nguyen, L. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.018 · Cited by 54
Hu, Y., Ehli, E. A., & Boomsma, D. I. (2017) · Autism Research · doi:10.1002/aur.1789 · Cited by 54
Brown, J. W., Whitehead, C. A., Basso, A. M., Rueter, L. E., & Zhang, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000739 · Cited by 52
Sokol, D. K., Dunn, D. W., Edwards, M. K., & Feinberg, J. R. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700401 · Cited by 52
Treating Functional Impairment of Autism with Selective Serotonin-Reuptake Inhibitors
Moore, M. L., Eichner, S. F., & Jones, J. R. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d543 · Cited by 51
Xie, S. L., Heuvelman, H., Magnusson, C., Rai, D., Lyall, K., Newschaffer, C. J., Dalman, C., Lee, B. K., & Abel, K. M. (2017) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.12413 · Cited by 51
SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents
Griebel, G., Pichat, P., Pruniaux, M., Beeské, S., Lopez‐Grancha, M., Genet, E., Terranova, J.-P., Castro, A., Sánchez, J. A., Black, M. D., et al. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.04.004 · Cited by 50
Gillberg, C., Lundström, S., Fernell, E., Nilsson, G., & Neville, B. G. R. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.05.027 · Cited by 50
Sheldrick, R. C., & Carter, A. S. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3568-z · Cited by 50
Kim, S., Shonka, S., French, W. P., Strickland, J., Miller, L., & Stein, M. A. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3125-1 · Cited by 46
Decreased parvalbumin mRNA levels in cerebellar Purkinje cells in autism
Soghomonian, J., Zhang, K., Reprakash, S., & Blatt, G. J. (2017) · Autism Research · doi:10.1002/aur.1835 · Cited by 46
Anagnostou, E. A., Esposito, K., Soorya, L. V., et al. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000227703.72117.bc · Cited by 44
Hoffman, K., Weisskopf, M. G., Roberts, A. L., Raz, R., Hart, J. E., Lyall, K., Hoffman, E. M., Laden, F., & Vieira, V. M. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx158 · Cited by 43
Hellmer, K., & Nyström, P. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.015 · Cited by 42
AlOlaby, R. R., Sweha, S. R., Silva, M., Durbin-Johnson, B. P., Yrigollen, C. M., Pretto, D. I., Hagerman, R. J., & Tassone, F. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.01.012 · Cited by 42
Hellings, J. A., Arnold, L. E., & Han, J. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1308483 · Cited by 40
Anshu, K., Nair, A. K., Kumaresan, U. D., Kutty, B. M., Srinath, S., & Laxmi, T. R. (2017) · Autism Research · doi:10.1002/aur.1852 · Cited by 40
Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder
Carminati, G. G., Gerber, F., Darbellay, B., Kosel, M., Deriaz, N., Chabert, J., Fathi, M., Bertschy, G., Ferrero, F., & Carminati, F. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.09.002 · Cited by 34
Ogata, H., Ihara, H., Murakami, N., Gito, M., Kido, Y., & Nagai, T. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36615 · Cited by 34
Neuropathology and Animal Models of Autism: Genetic and Environmental Factors
Gadad, B. S., Hewitson, L., Young, K. A., & German, D. C. (2013) · Autism Research and Treatment · doi:10.1155/2013/731935 · Cited by 33
Alachkar, A., Łażewska, D., Kieć‐Kononowicz, K., & Sadek, B. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00709 · Cited by 33
Self-citationCoruzzi, G., Pozzoli, C., Adami, M., Grandi, D., Guido, N., Smits, R. A., de Esch, I. J. P., & Leurs, R. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01396.x · Cited by 32
Stephan, D. A. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.12.003 · Cited by 31
Genetic variation in dopamine‐related gene expression influences motor skill learning in mice
Qian, Y., Chen, M., Forssberg, H., & Heijtz, R. D. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12062 · Cited by 30
The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats
Eissa, N., Khan, N., Ojha, S. K., Łażewska, D., Kieć‐Kononowicz, K., & Sadek, B. S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00042 · Cited by 30
Self-citationAn urgent need of experimental animal model of autism in drug development
Ruhela, R. K., Prakash, A., & Medhi, B. (2015) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.220210 · Cited by 26
Pharmacogenomics of Autism Spectrum Disorder
Brown, J. T., Eum, S., Cook, E. H., & Bishop, J. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0167 · Cited by 25
Pavăl, D., Rad, F., Rusu, R., Niculae, A.-Ş., Colosi, H. A., Dobrescu, I., & Dronca, E. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.3.229 · Cited by 25
Loxapine Add-on for Adolescents and Adults with Autism Spectrum Disorders and Irritability
Hellings, J. A., Reed, G. A., Cain, S., Zhou, X., Barth, F. X., Aman, M. G., Palaguachi, G. I., Mikhnev, D., Teng, R., Andridge, R., et al. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0003 · Cited by 24
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment
Deutsch, S. I. (2011) · InTech eBooks · doi:10.5772/976 · Cited by 22
Sahoo, S., Padhy, S. K., Singla, N., & Singh, A. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.012 · Cited by 21
Hendriksen, J. G. M., Klinkenberg, S., Collin, P., Wong, B. L. Y., Niks, E. H., & Vles, J. S. H. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.08.003 · Cited by 20
Robinson, W., Spiegel, R., & Schinzel, A. (1993) · Human Genetics · doi:10.1007/bf00222722 · Cited by 18
Andolina, D., Segni, M. D., & Ventura, R. (2016) · Oncotarget · doi:10.18632/oncotarget.13923 · Cited by 16
WALKER, B., Diefenbach, K., & PARIKH, T. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.008 · Cited by 15
Hong, M., Lee, S. Y., Han, J., Park, J. C., Lee, Y. J., Hwangbo, R., Chang, H., Cho, S. W., Bhang, S., Kim, B., et al. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.10.1687 · Cited by 15
Ellenbroek, B. A., August, C. L., & Youn, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00424 · Cited by 12
Lee, J., Kim, B., Kim, E., Howes, O. D., Cho, K. I. K., Yoon, Y. B., & Kwon, J. S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2642 · Cited by 11
Treatment options for the management of pervasive developmental disorders
Nash, K. A., & Carter, K. J. (2016) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636600 · Cited by 8
Cited by
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
Clinical practice guidelines for autism spectrum disorders
Subramanyam, A., Mukherjee, A., Dave, M., & Chavda, K. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_542_18 · Cited by 59
Arakawa, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.592408 · Cited by 32
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29
Metadata
- Authors
- Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-05-16
- Volume
- 12
- Pages
- 304-304
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2803899179
- Cited by
- 260
- References
- 245
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.